Allakos Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 61

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $30.6M

Allakos General Information

Description

Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation. Its portfolio consists of antibodies that target receptors, particularly Siglec-6, Siglec-8 and other anti-Siglec antibodies, including some antibodies in preclinical development.

Contact Information

Website
www.allakos.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 825 Industrial Road
  • Suite 500
  • San Carlos, CA 94070
  • United States
Primary Industry
Drug Delivery
Other Industries
Drug Discovery
Biotechnology
Acquirer
Concentra Biosciences
Vertical(s)
Life Sciences
Corporate Office
  • 825 Industrial Road
  • Suite 500
  • San Carlos, CA 94070
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Allakos Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
12. Merger/Acquisition 15-May-2025 $30.6M Completed Generating Revenue
11. PIPE 21-Sep-2022 Completed Generating Revenue
10. Secondary Transaction - Open Market Completed Generating Revenue
9. Merger/Acquisition 05-Dec-2019 Cancelled Generating Revenue
8. Secondary Transaction - Open Market Completed Generating Revenue
7. 2PO 02-Aug-2019 Completed Generating Revenue
6. PIPE 19-Jul-2018 Completed Generating Revenue
5. IPO 19-Jul-2018 Completed Generating Revenue
4. Early Stage VC (Series B) 15-Dec-2017 $100M $142M Completed Generating Revenue
3. Early Stage VC 16-Aug-2017 $42M Completed Startup
To view Allakos’s complete valuation and funding history, request access »

Allakos Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series B
Series A
To view Allakos’s complete cap table history, request access »

Allakos Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory recep
Drug Delivery
San Carlos, CA
61 As of 2024

South San Francisco, CA
 

Waltham, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Allakos Competitors (48)

One of Allakos’s 48 competitors is Corvus Pharmaceuticals, a Formerly VC-backed company based in South San Francisco, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Corvus Pharmaceuticals Formerly VC-backed South San Francisco, CA
Cogent Biosciences Formerly VC-backed Waltham, MA
Marker Therapeutics Formerly VC-backed Houston, TX
Kite Pharma Formerly VC-backed Santa Monica, CA
Coherus Oncology Formerly VC-backed Redwood City, CA
You’re viewing 5 of 48 competitors. Get the full list »

Allakos Patents

  • 136

    Total Documents Applications and Grants

  • Total Patents Families

  • 30

    Granted

  • 25

    Pending

  • Expiring in next 12 mo

Allakos Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025155802-A1 Anti-siglec-6 antibody formulations Pending 19-Jan-2024
WO-2025005961-A1 Anti-siglec-6 antibodies and methods of use thereof Inactive 30-Jun-2023
WO-2024254441-A1 Bispecific antibodies to siglec-6 and siglec-8 and methods of use thereof Inactive 08-Jun-2023
WO-2024043940-A1 Methods and compositions for treating atopic dermatitis Inactive 25-Aug-2022
WO-2024006820-A1 Anti-siglec-10 antibodies and methods of use thereof Inactive 29-Jun-2022 A61P29/00
To view Allakos’s complete patent history, request access »

Allakos Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Allakos Former Investors (27)

Investor Name Investor Type Holding Investor Since Participating Rounds
503 Partners Venture Capital Minority
Alta Partners Venture Capital Minority
BVF Partners Hedge Fund Minority
Braidwell Hedge Fund Minority
Capital Research and Management Company Asset Manager Minority
You’re viewing 5 of 27 investors. Get the full list »

Ready to get started?

Request a free trial

Allakos ESG

Risk Overview

Risk Rating

Updated March, 31, 2025

38.06 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,271

Rank

Percentile

Pharmaceuticals

Industry

of 908

Rank

Percentile

Biotechnology

Subindustry

of 406

Rank

Percentile

To view Allakos’s complete esg history, request access »

Allakos FAQs

  • When was Allakos founded?

    Allakos was founded in 2012.

  • Where is Allakos headquartered?

    Allakos is headquartered in San Carlos, CA.

  • What is the size of Allakos?

    Allakos has 61 total employees.

  • What industry is Allakos in?

    Allakos’s primary industry is Drug Delivery.

  • Is Allakos a private or public company?

    Allakos is a Private company.

  • What is the current valuation of Allakos?

    The current valuation of Allakos is .

  • What is Allakos’s current revenue?

    The current revenue for Allakos is .

  • How much funding has Allakos raised over time?

    Allakos has raised $431M.

  • Who are Allakos’s investors?

    503 Partners, Alta Partners, BVF Partners, Braidwell, and Capital Research and Management Company are 5 of 27 investors who have invested in Allakos.

  • Who are Allakos’s competitors?

    Corvus Pharmaceuticals, Cogent Biosciences, Marker Therapeutics, Kite Pharma, and Coherus Oncology are some of the 48 competitors of Allakos.

  • When was Allakos acquired?

    Allakos was acquired on 15-May-2025.

  • Who acquired Allakos?

    Allakos was acquired by Concentra Biosciences.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process